Does anyone know this drug 177-Lu-HTK03170

[Islandboy2021]

Is this drug 177-Lu-HTK03170 just another Lu-177 drug with a different drug company? I am going to start a phase one trial with this drug.

[rasher1]

hello, did you get this trial in Vancouver?

[Islandboy2021]

This is a trial that is going to happen in Vancouver. It hasn't started yet.

[Mbnm]

Dr Eigl arranging this ? How is it different from Pluvicto ?

[j-o-h-n]

From Mr. Google

Oncidium Foundation Logo

177Lu-HTK03170 is the therapeutic 177Lu-labeled analogue of 68Ga-HTK03149, itself based on the molecule HTK03041. These molecules are developed at BC Cancer, Vancouver, Canada as PSMA targeting drugs intended to be used in the therapy of late stage metastasized prostate cancer. A Phase I/II trial with the pair 68Ga-HTK03149/177Lu-HTK03170 has been initiated in December 2022 and is supposed to be completed by end of 2026.

Target/Mechanism: PSMA

Carrier/Ligand: PSMA

Radiation Type: beta electrons (β–)

Good Luck, Good Health and Good Humor.

j-o-h-n

[gsun]

Keep us informed please. I am at BC Cancer too.